Gene shot for failing hearts shows early safety in tiny trial
NCT ID NCT01422772
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This early-stage study tested whether a gene medicine called VM202 is safe to inject directly into heart muscle areas that couldn't be fully fixed during bypass surgery. Nine adults with ischemic heart disease took part. The main goal was to check for side effects over six months, not to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC HEART DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seoul National University Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.